Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02596971
- Locations
- 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- OrphAI Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT02594384
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Horizon Oncology Research, Inc., Lafayette, Indiana, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT02541604
- Locations
- 🇨🇭
Universitäts-Kinderspital; Abteilung für Onkologie, Zürich, Switzerland
🇮🇹Azienda Ospedaliera di Padova; Clinica di Onco-ematologia pediatrica, Padova, Veneto, Italy
🇪🇸Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02530489
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT02508870
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸City of Hope, Duarte, California, United States
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT02500407
- Locations
- 🇬🇧
Barts Cancer Institute, London, United Kingdom
🇬🇧Royal Marsden Hospital; Institute of Cancer Research; Pharmacy Stores, Sutton, United Kingdom
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1280
- Registration Number
- NCT02486718
- Locations
- 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷Hôpital Universitaire Dupuytren, Limoges, France
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT02471846
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Neoadjuvant Atezolizumab in Localized Bladder Cancer
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Lawrence Fong
- Target Recruit Count
- 23
- Registration Number
- NCT02451423
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 809
- Registration Number
- NCT02450331
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Fairview Hospital; Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.